» Articles » PMID: 38281067

Awakening the Sleeping Giant: Epstein-Barr Virus Reactivation by Biological Agents

Overview
Journal Pathog Dis
Date 2024 Jan 28
PMID 38281067
Authors
Affiliations
Soon will be listed here.
Abstract

Epstein-Barr virus (EBV) may cause harm in immunocompromised conditions or on stress stimuli. Various chemical agents have been utilized to induce the lytic cycle in EBV-infected cells. However, apart from chemical agents and external stress stimuli, certain infectious agents may reactivate the EBV. In addition, the acute infection of other pathogens may provide suitable conditions for EBV to thrive more and planting the roots for EBV-associated pathologies. Various bacteria such as periodontal pathogens like Aggregatibacter, Helicobacter pylori, etc. have shown to induce EBV reactivation either by triggering host cells directly or indirectly. Viruses such as Human simplex virus-1 (HSV) induce EBV reactivation by HSV US3 kinase while other viruses such as HIV, hepatitis virus, and even novel SARS-CoV-2 have also been reported to cause EBV reactivation. The eukaryotic pathogens such as Plasmodium falciparum and Aspergillus flavus can also reactivate EBV either by surface protein interaction or as an impact of aflatoxin, respectively. To highlight the underexplored niche of EBV reactivation by biological agents, we have comprehensively presented the related information in this review. This may help to shedding the light on the research gaps as well as to unveil yet unexplored mechanisms of EBV reactivation.

Citing Articles

Immune Modulation by Epstein-Barr Virus Lytic Cycle: Relevance and Implication in Oncogenesis.

Todorovic N, Ambrosio M, Amedei A Pathogens. 2024; 13(10).

PMID: 39452747 PMC: 11510492. DOI: 10.3390/pathogens13100876.


Comparative Study Analysis of Epstein-Barr Virus Infection: Tissue Versus Blood Samples in Patients With Prostatic Adenocarcinoma and Its Correlation With Clinicopathological Parameters.

Mharrach I, Tadlaoui K, Laraqui A, Ennibi K, Hamedoun L, Ameur A Cureus. 2024; 16(8):e66048.

PMID: 39224737 PMC: 11367065. DOI: 10.7759/cureus.66048.


Characterization of latently infected EBV+ antibody-secreting B cells isolated from ovarian tumors and malignant ascites.

Zhang L, Strange M, Elishaev E, Zaidi S, Modugno F, Radolec M Front Immunol. 2024; 15:1379175.

PMID: 39086481 PMC: 11288875. DOI: 10.3389/fimmu.2024.1379175.


Transverse Myelitis: A Case-Based Discussion of Infectious Etiologies.

Singh D, deFisser G, Samuel S, Chennu N, Polhemus L, Rodriguez W Cureus. 2024; 16(6):e63079.

PMID: 39055452 PMC: 11269968. DOI: 10.7759/cureus.63079.

References
1.
Dehee A, Asselot C, Piolot T, Jacomet C, Rozenbaum W, Vidaud M . Quantification of Epstein-Barr virus load in peripheral blood of human immunodeficiency virus-infected patients using real-time PCR. J Med Virol. 2001; 65(3):543-52. View

2.
Neofytou E, Sourvinos G, Asmarianaki M, Spandidos D, Makrigiannakis A . Prevalence of human herpes virus types 1-7 in the semen of men attending an infertility clinic and correlation with semen parameters. Fertil Steril. 2008; 91(6):2487-94. DOI: 10.1016/j.fertnstert.2008.03.074. View

3.
Farrell P . Epstein-Barr Virus and Cancer. Annu Rev Pathol. 2018; 14:29-53. DOI: 10.1146/annurev-pathmechdis-012418-013023. View

4.
Liu X, Li Y, Peng S, Yu X, Li W, Shi F . Epstein-Barr virus encoded latent membrane protein 1 suppresses necroptosis through targeting RIPK1/3 ubiquitination. Cell Death Dis. 2018; 9(2):53. PMC: 5833833. DOI: 10.1038/s41419-017-0081-9. View

5.
Brooks B, Tancredi C, Song Y, Mogus A, Huang M, Zhu H . Epstein-Barr Virus and Human Herpesvirus-6 Reactivation in Acute COVID-19 Patients. Viruses. 2022; 14(9). PMC: 9504756. DOI: 10.3390/v14091872. View